ARch Biopartners (QB) Aktie - ACHFF

ARch Biopartners Inc (QB) (ACHFF) Aktie

Professionelle Tools für Privatanleger.

Premium

Current Price

0,5984

( 5,44% )

Gebot

0,493

Fragen

0,5984

Volumen

12.050

Durchschnittliches Volumen (3 Mio.)

US$ 0

Finanzvolumen

US$ 6.928

0,56 Tagesbereich 0,5984

0,2881 52-Wochen-Bereich 1,285

Marktkapitalisierung

40,651M

Unternehmenswert

55,9M

Handelsende

0,5675

Handelsbeginn

0,561

Letzte Trade

1000

0.5984

Letzter Handelszeitpunkt

VWAP

0,574923

Erlöse (LTM)

158,08k

Nettogewinn (LTM)

-2,78M

Ausgegebene Aktien

67.933.289

Streubesitz (%)

78,03%

Institutioneller Besitz (%)

Dividendenrendite (LTM)

Kurs-Gewinn-Verhältnis

-18,93

Kurs-Umsatz-Verhältnis (KUV)

339,11

Gewinn pro Aktie (EPS)

-0,04

Beta

1,76

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experience... Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada. Mehr anzeigen

Sektor

Branche

Website

www.archbiopartners.com

Hauptsitz

Toronto, Canada

Gegründet

ARch Biopartners Inc (QB) is listed in the sector of the OTC Markets with ticker ACHFF. The last closing price for ARch Biopartners (QB) was US$0,57. Over the last year, ARch Biopartners (QB) shares have traded in a share price range of US$ 0,2881 to US$ 1,285.

ARch Biopartners (QB) currently has 67.933.289 shares in issue. The market capitalisation of ARch Biopartners (QB) is US$40,65 million. ARch Biopartners (QB) has a price to earnings ratio (PE ratio) of -18.93.

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF...

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

TORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.0116	-1.90163934426	0.61	0.63	0.5368	10553	0.54227896	CS
4	0.2544	73.9534883721	0.344	0.79	0.33622	37506	0.57621115	CS
12	0.2434	68.5633802817	0.355	0.79	0.2881	30591	0.43190342	CS
26	-0.32565	-35.2415994805	0.92405	1.0165	0.2881	31611	0.53531644	CS
52	-0.6536	-52.2044728435	1.252	1.285	0.2881	32834	0.75604259	CS
156	-0.9766	-62.0063492063	1.575	1.88	0.2881	19736	0.97529845	CS
260	-0.4266	-41.6195121951	1.025	4.13	0.2881	17782	1.26259665	CS

ACHFF - Frequently Asked Questions (FAQ)

What is the current ARch Biopartners Inc (QB) share price?

The current share price of ARch Biopartners Inc (QB) is US$ 0,5984

How many ARch Biopartners Inc (QB) shares are in issue?

ARch Biopartners Inc (QB) has 67.933.289 shares in issue

What is the market cap of ARch Biopartners Inc (QB)?

The market capitalisation of ARch Biopartners Inc (QB) is USD 40,65M

What is the 1 year trading range for ARch Biopartners Inc (QB) share price?

ARch Biopartners Inc (QB) has traded in the range of US$ 0,2881 to US$ 1,285 during the past year

What is the PE ratio of ARch Biopartners Inc (QB)?

The price to earnings ratio of ARch Biopartners Inc (QB) is -18,93

What is the cash to sales ratio of ARch Biopartners Inc (QB)?

The cash to sales ratio of ARch Biopartners Inc (QB) is 339,11

What is the registered address of ARch Biopartners Inc (QB)?

The registered address for ARch Biopartners Inc (QB) is 545 King Street West, Toronto, Ontario, M5V 1M1

What is the ARch Biopartners Inc (QB) website address?

The website address for ARch Biopartners Inc (QB) is www.archbiopartners.com

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

ARch Biopartners Inc (QB) (ACHFF)

ARch Biopartners Inc (QB) (ACHFF) Aktie

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über ARch Biopartners Inc (QB)

ACHFF Neueste Nachrichten

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

ACHFF - Frequently Asked Questions (FAQ)

ACHFF Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen